• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在痔病治疗中的微粒化纯化黄酮类混合物。

Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease.

机构信息

Institut Mutualiste Monsouris, Paris, France.

Department of Colorectal Surgery, Saifee Hospital, Mumbai, India.

出版信息

J Comp Eff Res. 2021 Jul;10(10):801-813. doi: 10.2217/cer-2021-0038. Epub 2021 Apr 30.

DOI:10.2217/cer-2021-0038
PMID:33928786
Abstract

Hemorrhoidal disease (HD) is common in adults. Treatment is largely conservative, although more invasive procedures may be required. Venoactive drugs such as micronized purified flavonoid fraction (MPFF) are widely used, but a recent and comprehensive review of supporting evidence is lacking. In acute HD, MPFF can reduce HD symptoms such as bleeding, pain, anal discomfort, anal discharge and pruritus. In patients undergoing surgery, postoperative adjunct MPFF consistently reduces pain, bleeding duration and use of analgesia. MPFF treatment is appropriate and effective both as a first-line conservative treatment and as a postoperative adjunct treatment. MPFF reduces the duration of hospital stay following surgery, facilitating a return to normal activity and improving quality of life. MPFF may also prevent HD recurrence.

摘要

痔病(HD)在成年人中很常见。治疗主要采用保守方法,但也可能需要更具侵袭性的方法。静脉活性药物如微粒化纯化黄酮类混合物(MPFF)被广泛应用,但缺乏对其支持证据的近期全面审查。在急性 HD 中,MPFF 可减轻出血、疼痛、肛门不适、肛门分泌物和瘙痒等症状。对于接受手术的患者,术后辅助应用 MPFF 可持续减轻疼痛、出血持续时间和镇痛药物的使用。MPFF 作为一线保守治疗和术后辅助治疗均合理有效。MPFF 可缩短手术后的住院时间,促进恢复正常活动并提高生活质量。MPFF 还可能预防 HD 复发。

相似文献

1
Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease.在痔病治疗中的微粒化纯化黄酮类混合物。
J Comp Eff Res. 2021 Jul;10(10):801-813. doi: 10.2217/cer-2021-0038. Epub 2021 Apr 30.
2
Micronized Purified Flavonoid Fraction in Hemorrhoid Disease: A Systematic Review and Meta-Analysis.在痔病中应用微粒化纯化黄酮类混合物:系统评价和荟萃分析。
Adv Ther. 2020 Jun;37(6):2792-2812. doi: 10.1007/s12325-020-01353-7. Epub 2020 May 12.
3
Conservative Treatment of Hemorrhoids: Results of an Observational Multicenter Study.痔疮的保守治疗:一项观察性多中心研究结果。
Adv Ther. 2018 Nov;35(11):1979-1992. doi: 10.1007/s12325-018-0794-x. Epub 2018 Oct 1.
4
Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease.微粉化纯化黄酮类化合物1000毫克片剂与500毫克片剂治疗急性痔病患者的临床可接受性研究
Curr Med Res Opin. 2016 Nov;32(11):1821-1826. doi: 10.1080/03007995.2016.1211520. Epub 2016 Aug 25.
5
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study).一项评估痔病保守治疗的国际观察性研究:CHORALIS(急性痔病评估国际研究)的结果。
J Comp Eff Res. 2024 Oct;13(10):e240070. doi: 10.57264/cer-2024-0070. Epub 2024 Aug 12.
6
Efficacy and safety of micronized purified flavonoid fractions for the treatment of postoperative hemorrhoid complications: A systematic review and meta-analysis.微粉化纯化黄酮类混合物治疗痔术后并发症的疗效和安全性:系统评价和荟萃分析。
Phytomedicine. 2022 Sep;104:154244. doi: 10.1016/j.phymed.2022.154244. Epub 2022 Jun 17.
7
Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review.痔病的复发率和药物治疗:系统评价。
Adv Ther. 2023 Jan;40(1):117-132. doi: 10.1007/s12325-022-02351-7. Epub 2022 Nov 4.
8
Clinical use of micronized purified flavonoid fraction for treatment of symptoms after hemorrhoidectomy: results of a randomized, controlled, clinical trial.微粉化纯化黄酮类成分治疗痔切除术后症状的临床应用:一项随机对照临床试验的结果
Dis Colon Rectum. 2004 May;47(5):704-10. doi: 10.1007/s10350-003-0119-1. Epub 2004 Mar 25.
9
The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes.微粉化纯化黄酮类成分对急性痔发作治疗的影响。
Curr Med Res Opin. 2006 Jun;22(6):1141-7. doi: 10.1185/030079906X104803.
10
Treatment of haemorrhoidal disease with micronized purified flavonoid fraction and sucralfate ointment.采用微粒化纯化黄酮类化合物和硫酸锌软膏治疗痔疮病。
Acta Biomed. 2020 Mar 19;91(1):139-141. doi: 10.23750/abm.v91i1.9361.

引用本文的文献

1
Comparison of efficacy and safety between surgical and conservative treatments for hemorrhoids: a meta-analysis.痔疮手术治疗与保守治疗的疗效及安全性比较:一项荟萃分析
BMC Gastroenterol. 2025 Jul 1;25(1):492. doi: 10.1186/s12876-025-04089-2.
2
The bidirectional association between hemorrhoidal disease and varicose veins: a nationwide population-based cohort study.痔病与静脉曲张之间的双向关联:一项基于全国人群的队列研究。
Int J Colorectal Dis. 2025 Apr 11;40(1):91. doi: 10.1007/s00384-025-04889-8.
3
The Italian Unitary Society of Colon-Proctology (Società Italiana Unitaria di Colonproctologia) guidelines for the management of acute and chronic hemorrhoidal disease.
意大利结肠直肠病统一学会(Società Italiana Unitaria di Colonproctologia)关于急慢性痔病管理的指南。
Ann Coloproctol. 2024 Aug;40(4):287-320. doi: 10.3393/ac.2023.00871.0124. Epub 2024 Aug 30.
4
An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study).一项评估痔病保守治疗的国际观察性研究:CHORALIS(急性痔病评估国际研究)的结果。
J Comp Eff Res. 2024 Oct;13(10):e240070. doi: 10.57264/cer-2024-0070. Epub 2024 Aug 12.
5
: 2022 year in review.2022年回顾
J Comp Eff Res. 2023 Apr;12(4):e230026. doi: 10.57264/cer-2023-0026. Epub 2023 Mar 14.
6
Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review.痔病的复发率和药物治疗:系统评价。
Adv Ther. 2023 Jan;40(1):117-132. doi: 10.1007/s12325-022-02351-7. Epub 2022 Nov 4.
7
Evaluation of the Efficacy and Safety of a Compound of Micronized Flavonoids in Combination With Vitamin C and Extracts of , , and for the Reduction of Hemorrhoidal Symptoms in Patients With Grade II and III Hemorrhoidal Disease: A Retrospective Real-Life Study.微粉化黄酮类化合物联合维生素C及[此处原文缺失部分植物名称]提取物治疗Ⅱ、Ⅲ度痔病患者以减轻痔症状的疗效与安全性评估:一项回顾性真实世界研究
Front Pharmacol. 2021 Dec 14;12:773320. doi: 10.3389/fphar.2021.773320. eCollection 2021.